WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006011631) THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2006/011631 International Application No.: PCT/JP2005/014136
Publication Date: 02.02.2006 International Filing Date: 27.07.2005
IPC:
C07D 277/46 (2006.01) ,A61K 31/426 (2006.01)
Applicants: INOUE, Takayuki[JP/JP]; JP (UsOnly)
TOJO, Takashi[JP/JP]; JP (UsOnly)
MORITA, Masataka[JP/JP]; JP (UsOnly)
ASTELLAS PHARMA INC.[JP/JP]; 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411, JP (AllExceptUS)
Inventors: INOUE, Takayuki; JP
TOJO, Takashi; JP
MORITA, Masataka; JP
Agent: TAKASHIMA, Hajime; Meiji Yasuda Seimei Odaka Midosuji Bldg. 1-1, Fushimimachi 4-chome Chuo-ku, Osaka-shi Osaka 541-0044, JP
Priority Data:
200490419627.07.2004AU
Title (EN) THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY
(FR) DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1
Abstract: front page image
(EN) A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
(FR) L'invention concerne un composé de formule (I), (II), (III) ou (IV), dans lesquelles chaque symbole est spécifié dans la description, ou un de ses sels pharmaceutiquement acceptables, utilisés en tant qu'inhibiteur (VAP-1) de la protéine 1 d'adhésion vasculaire, une composition pharmaceutique, et un procédé pour prévenir ou traiter une maladie associée à la VAP-1, en particulier un oedème maculaire. Ledit procédé comprend l'administration d'une quantité efficace du composé ou d'un de ses sels pharmaceutiquement acceptable à un sujet, et analogues.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)